Journal articleFuture Oncol2023
Response heterogeneity as a new biomarker of treatment response in patients with neuroendocrine tumors.
- Journal
- Future Oncol
- Published
- 27 July 2023
- Citations
- 4
- License
- cc by-nc-nd
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract cc by-nc-nd
Aim: The RAISE project aimed to find a surrogate end point to predict treatment response early in patients with enteropancreatic neuroendocrine tumors (NET). Response heterogeneity, defined as the coexistence of responding and non-responding lesions, has been proposed as a predictive marker for progression-free survival (PFS) in patients with NETs. … Excerpt only: this text is the publisher’s. Read it in full at the source.